(Q40617724)

22 September 2017

title

Antitumor effect of arsenic trioxide in murine xenograft model (English)

1 reference

22 September 2017

1 reference

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

31 March 2024

author name string

Mariko Kito

1

1 reference

22 September 2017

Kenji Matsumoto

2

1 reference

22 September 2017

Naoko Wada

3

1 reference

22 September 2017

Kouichiro Sera

4

1 reference

22 September 2017

Shoji Futatsugawa

5

1 reference

22 September 2017

Tomoki Naoe

6

1 reference

22 September 2017

Yoshinori Nozawa

7

1 reference

22 September 2017

Yukihiro Akao

8

1 reference

22 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14611680

31 March 2024

publication date

1 November 2003

1 reference

full work available at URL

22 September 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1349-7006.2003.tb01393.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14611680

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1349-7006.2003.tb01393.x

31 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2003.tb01393.x

31 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

31 March 2024

1 reference

22 September 2017

volume

94

1 reference

22 September 2017

issue

11

1 reference

22 September 2017

page(s)

1010-1014

1 reference

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Overview of bladder cancer trials in the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01393.X

Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis

21 January 2018

14

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown

31 March 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

Arsenic trioxide in multiple myeloma: rationale and future directions

31 March 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2003.TB01393.X

31 March 2024

Identifiers

1 reference

22 September 2017

1 reference